· Epeleuton reduced the annualised rate of vaso-occlusive crises (VOCs) leading to a healthcare visit by 57.4% versus the prior-year baseline (p=0.0001). · 62.1% of evaluable […]
Dublin, Ireland, 5 November 2025: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced that enrolment has successfully completed in the first clinical trial […]